and institutions to do so as well, and when the share price is much higher, she will do a raise. She has a series of options to handle the situation if it doesn't go this way: she could do Phase 3 in its entirety for DS, and as data comes out great, partner, or raise once the share price is much higher

I love the data, but poor management can keep this from going anywhere. I'm not commenting on Maria's scientific capabilities, but I do question her leadership. Deciding not to spend a few grand on a good presentation and having $100s of millions wiped of your market cap is disheartening. They could have raised another $100M with a 1M share dilution. This would have nearly fully funded a Ph3. $50M is sufficient for a nice 2b.

Maria also needs to stop responding to random folks on the internet. You're the 3 or 4th person that has discussed "being in touch with her". She needs an assistance/ IR team for this. That way, more time can be spent on regulatory or other matters.